Clinical Trials Logo

Tooth Diseases clinical trials

View clinical trials related to Tooth Diseases.

Filter by:
  • Not yet recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06348953 Not yet recruiting - Dental Caries Clinical Trials

Bioactive Versus Non-Bioactive Restorative System in Deep Carious Molars

Start date: April 2024
Phase: N/A
Study type: Interventional

This research study delves into the effectiveness of bioactive and non-bioactive restorative systems in deep carious permanent molars treated with selective caries removal. Selective caries removal techniques aim to preserve as much healthy tooth structure as possible while effectively eliminating carious tissue. The study investigates how the choice of restorative material influences the outcomes of selective caries removal procedures in deep carious lesions. By assessing factors such as restoration integrity, pulpal response, and long-term success rates, the research seeks to provide evidence-based insights into the comparative performance of bioactive and non-bioactive restorative systems in this clinical context.

NCT ID: NCT06218134 Not yet recruiting - Clinical trials for Charcot-Marie-Tooth Disease, Type 1

Evaluate the Safety and Potential Efficacy of Human Wharton's Jelly-derived Mesenchymal Stem Cells With Charcot-Marie-Tooth Disease Type 1E

Start date: March 30, 2024
Phase: N/A
Study type: Interventional

Charcot-Marie-Tooth disease (CMT) is a hereditary peripheral nerve disease that causes causes muscle atrophy, muscle weakness, sensory loss, balance disorder, gait disorder, blindness, hearing disorder, breathing disorder, vocal cord paralysis, foot deformity, scoliosis, and reflex dysfunction, More than 140 types of genes causing this disease are known. Charcot-Marie-Tooth (CMT) 1E, the target disease of this study, shows very severe symptoms compared to other Charcot-Marie-Tooth types. In cases of early onset, especially in children under 5 years of age, almost all patients are unable to walk without a wheelchair and have severe illness. Symptoms include scoliosis, breathing problems, vocal cord paralysis, foot deformity, loss of sensation and reflex function. Additionally, more than 40% of Charcot-Marie-Tooth (CMT) 1E patients have hearing loss and become unable to live without hearing aids. Although this disease is very disabling, there is still no approved treatment. To date, there is a lack of practical treatment or treatment support methods that can change the progression of hereditary motor and sensory neuropathy, so the focus is on pain control, use of assistive devices, and rehabilitation treatment, but the treatment effect is almost non-existent. This study is conducted for the purpose of confirming the safety and exploratory treatment effect by administering EN001, an allogeneic umbilical cord-derived mesenchymal stem cell, once intravenously to patients with Charcot-Marie-Tooth (CMT) 1E. EN001 is an allogeneic (alien-derived) umbilical cord-derived mesenchymal stem cell, and a phase 1 clinical trial of single intravenous administration was completed in 9 Charcot-Marie-Tooth (CMT) type 1A patients. Among the four adverse reactions that occurred in the participating research subjects, there were no adverse drug reactions related to EN001, and all four cases were mild and recovered. No serious adverse drug reactions or infusion reactions were observed in any study subjects, so this is a safe stem cell treatment. Through efficacy tests and non-clinical tests, the effectiveness of improving behavior and increasing nerve and motor conduction speeds when administering the test drug to animal models of muscle disease was confirmed, so it is expected that this study can stabilize the disease progression in patients, and it will contribute to improving the quality of life and further promoting public health and welfare.

NCT ID: NCT06151600 Not yet recruiting - Clinical trials for Peripheral Neuropathy

A Prospective Natural History and Outcome Measure Discovery Study of Charcot-Marie-Tooth Disease, Type 4J

CMT4J
Start date: March 1, 2024
Phase:
Study type: Observational

This is a multicenter, longitudinal, prospective observational natural history study of subjects with a molecularly confirmed diagnosis of CMT4J. The study will enroll 20 subjects of any age into a uniform protocol for follow-up and evaluations. Subject visits will occur every 12 months + 4 weeks for up to 2 years.

NCT ID: NCT05925179 Not yet recruiting - Tooth Diseases Clinical Trials

Effects of Antibiotic Prophylaxis on the Healing Parameters Following Surgical Crown Lengthening

SCLABP
Start date: August 1, 2023
Phase: Phase 4
Study type: Interventional

The goal of this clinical trial is to test the effects of prophylactic antibiotics in healthy individuals who are in need of surgical crown lengthening. The main question it aims to answer is if single dose antibiotics prior to surgical crown lengthening has any effects on the healing outcomes. Participants will be asked to take either - 2 g of amoxicillin + clavulanate, or - placebo, one hour prior to surgery and without knowing what medicine they took. Researchers will compare the wound healing and self-reported outcomes of the antibiotics group and placebo group.

NCT ID: NCT05792800 Not yet recruiting - Caries,Dental Clinical Trials

Dental Practitioners KAP Regarding Caries Preventive Measures in Cairo and Riyadah

Start date: September 2023
Phase:
Study type: Observational

The study aims to evaluate the knowledge, attitude, and practice of dental practitioners from Cairo and Riyadh regarding caries preventive measures.

NCT ID: NCT05792215 Not yet recruiting - Caries,Dental Clinical Trials

KAP of Dental Practitioners Regarding CRA

Start date: September 2023
Phase:
Study type: Observational

The aim of the study is to evaluate the knowledge, attitude, and practice of a group of dental practitioners from Cairo and Riyadh regarding caries risk assessment and management.

NCT ID: NCT05777226 Not yet recruiting - Clinical trials for Charcot-Marie-Tooth Disease (CMT)

Research of SORD-CMT Natural History and Epalrestat Treatment

SORD-CMT
Start date: April 2023
Phase: Phase 2
Study type: Interventional

Charcot-Marie-Tooth disease (CMT) is a group of the most common hereditary peripheral neuropathy with high clinical and genetic heterogeneity. Biallelic pathogenic variants in SORD gene leading to loss of function of SORD protein cause axonal degeneration. Current research suggests that SORD-CMT2 may be the most common subtype of AR-CMT2. The primary purpose of this study is to explore the natural history of SORD-CMT2 patients by detecting the ONLS scale score and serum sorbitol level changes at 6th, 12th, 24th, and 36th months and to evaluate the effectiveness and safety of epalrestat. Patients with strong treatment willingness and voluntary purchase of drugs are included in the epalrestat treatment group, and patients without drug treatment willingness are included in the control group. Patients in the drug treatment group take epalrestat (50 mg) orally three times daily. This study is expected to be carried out simultaneously in 5 hospitals in mainland China. About 30 SORD-CMT2 patients will be enrolled in this study, and the study period will be 36 months.

NCT ID: NCT04946617 Not yet recruiting - Clinical trials for Periodontal Diseases

Chlorhexidine and Essential Oil Mouthwashes on Human Beta-Defensin 2 (hbD2) and Kathelicidin (LL-37) Saliva Levels

hbD2
Start date: July 20, 2021
Phase:
Study type: Observational [Patient Registry]

Recent studies have shown that while mouthwashes exhibit antimicrobial properties against bacteria and their products, at the same time showing the cytotoxic effect on living cells in the mouth.29 To the best of our knowledge, there is no information about the toxicity effect of these two mouthwashes, which are highly preferred, on antimicrobial peptides secreted from the oral epithelium. Therefore, our aim in this study is to evaluate the effect of chlorhexidine and essential oil mouthwash on hBD2 and LL-37 in saliva.

NCT ID: NCT03397303 Not yet recruiting - Clinical trials for Chronic Inflammatory Demyelinating Polyneuropathy

Quantification of Nerve Stiffness in Neuropathies

Nerf_SSI
Start date: April 2018
Phase: N/A
Study type: Interventional

This project aims to understand how nerve mechanical properties are altered in patients with rare peripheral neuropathies . Stiffness of various peripheral nerves will be measured using ultrasound shear wave elastography. Patients will be compared with age-matched controls.

NCT ID: NCT01289704 Not yet recruiting - Clinical trials for Charcot-Marie-Tooth Disease

Treadmill, Stretching and Proprioceptive Exercise (TreSPE) Rehabilitation Program for Charcot−Marie−Tooth Neuropathy Type 1A (CMT1A)

TreSPE
Start date: February 2011
Phase: Phase 2/Phase 3
Study type: Interventional

Charcot−Marie−Tooth neuropathy type 1A (CMT1A) is one of the most common inherited neurological disorders. The study will evaluate the efficacy and safety of an innovative rehabilitation protocol constituted by exercises at the treadmill and by a stretching and proprioceptive approach. A total of 92 patients will be enrolled in the study and treated in a controlled, randomized, single blind, way. To recruit a high number of patients with CMT1A the study will be multicentric and will comprehend four of the most active clinical centers in the field of CMT, in Italy. People with CMT1A are very motivated in entering rehabilitation protocols because to date there is no effective therapy for this disease. Therefore, the investigators expect a high compliance by the patients. With the present project the investigators plan to clarify several unanswered questions: 1) the efficacy and safety of treadmill over a more conventional protocol; 2) the duration and frequency of any rehabilitation treatment; 3) the most sensitive outcome measures to evaluate the efficacy of rehabilitation approach in patients with CMT.